The virus takes control of three key host proteins that suppress the activity of the complement system. Researchers at the ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has unveiled encouraging preliminary data from the Phase 1 portion of its OCU410 ...

Researchers have discovered that SARS-CoV-2 hijacks three important host proteins that dampen the activity of the complement system, a key component of early antiviral immunity. This significantly ...

Researchers at the Hebrew University of Jerusalem have developed an innovative approach to fight antibiotic-resistant ...

The eye-care company Alcon Research has entered into licensing and purchase option agreements with Potentia Pharmaceuticals to develop Potentia's leading drug candidate — a complement pathway ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of ...

Annexon Biosciences (ANNX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew ...

Needham analyst Joseph Stringer maintained a Buy rating on Annexon Biosciences (ANNX – Research Report) today and set a price target of ...